IA
BMY.RT

Independence Advisors’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Independence Advisors’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$3K Hold
1,200
– – ﹤0.01% 163
2020
Q2 		$4K Buy
+1,200
New +$4.33K ﹤0.01% 157
2020
Q1 		– Sell
-1,200
Closed -$4K – 168
2019
Q4 		$4K Buy
+1,200
New +$3.12K ﹤0.01% 153

Other funds holding BMY.RT

LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Independence Advisors's BMY.RT Position: Q3 2020 in Review

Independence Advisors held its Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) position steady in Q3 2020 at 1,200 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #163.

Independence Advisors first reported a position in BMY.RT in Q4 2019 and has held it in 3 quarters since. The position peaked at $4K in Q2 2020. 571 funds tracked by Wall St. Rank hold BMY.RT as of Q3 2020.

  • Independence Advisors held 1,200 shares of Bristol-Myers Squibb Company Contingent Value Rights worth $3K as of Q3 2020.
  • Independence Advisors left its Bristol-Myers Squibb Company Contingent Value Rights share count unchanged in Q3 2020.
  • Bristol-Myers Squibb Company Contingent Value Rights made up ﹤0.01% of Independence Advisors's portfolio in Q3 2020, its #163 holding.
  • Independence Advisors first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and has held it in 3 quarters since.
  • Independence Advisors's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $4K in Q2 2020.
  • 571 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q3 2020.

Based on Independence Advisors's 13F filing for Q3 2020, filed 4 Nov 2020.